20

Dexrazoxane

20 Publications Verification

Cat. No.: HY-B0581

CAS No.: 24584-09-6

Synonyms: ICRF-187; ADR-529; NSC-169780

Target:

Ferroptosis Apoptosis

Research Areas:

Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer

Dexrazoxane, as an intracellular iron chelating agent, reduces the formation of superoxide radicals and has cardioprotective, anti-inflammatory, antioxidant, anti-tumor and neuroprotective activities. Dexrazoxane inhibits ferroptosis of H9c2 cells by inhibiting HMGB1. Dexrazoxane induces DNA damage and apoptosis in human fibrosarcoma cells .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

13

2-NP

13 Cited Publications

Cat. No.: HY-W013523

CAS No.: 65182-56-1

Target:

STAT JAK HSV

Research Areas:

Infection Cancer

2-NP is a selective enhancer of STAT1 transcription. 2-NP can enhance the ability of IFN-γ to inhibit the proliferation of human breast cancer and fibrosarcoma cells .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

(S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine

1 Cited Publications

Cat. No.: HY-147025

CAS No.: 2347517-69-3

Purity: 99.06%

Target:

PROTACs TGF-beta/Smad HIF/HIF Prolyl-Hydroxylase

Research Areas:

Cardiovascular Disease Inflammation/Immunology Cancer

(S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine is a dual-targeting PROTAC molecule. (S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine not only targets the ubiquitination and degradation of Smad3, but also elevates the protein level of HIF-α, thereby exerting multi-pathway anti-fibrotic and renoprotective effects. (S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine can be used in a wide range of tumor studies including cancers with KRAS inhibitor resistance, covering pancreatic ductal adenocarcinoma, acute myeloid leukemia, and various soft tissue sarcomas (such as fibrosarcoma, liposarcoma, chondrosarcoma, etc.). (S,R,S)-AHPC-C2-amide-benzofuranylmethyl-pyridine can also be applied to research related to various solid tumors and hematological malignancies, involving multiple cancer types such as colon cancer, breast cancer, ovarian cancer, non-small cell lung cancer, glioblastoma, and melanoma .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

JMJD1C-IN-1

Cat. No.: HY-162275

CAS No.: 861224-48-8

Target:

Histone Demethylase Histone Methyltransferase STAT

Research Areas:

Cancer

JMJD1C-IN-1 is an orally active and selective inhibitor of JMJD1C (IC₅₀ = 0.59 μM, K_d = 1.96 μM). JMJD1C-IN-1 inhibits the binding of JMJD1C to H3K9me2 peptide substrate in the HTRF assay (IC₅₀ = 1.47 μM). JMJD1C-IN-1 disrupts intratumoral regulatory T (Treg) cell fitness by dual mechanisms: promoting H3K9me2 accumulation to downregulate PD1 expression and reducing STAT3 demethylation to enhance STAT3 activation. JMJD1C-IN-1 demonstrates dose-dependent antitumor efficacy in multiple mouse tumor models (MCA205 fibrosarcoma, B16-F10 melanoma, LLC lung cancer, Hepa1-6 hepatocellular carcinoma, CT26 colorectal cancer). JMJD1C-IN-1 can be used for the study of tumor immunotherapy by selectively targeting intratumoral Treg cells .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

PROTAC GPX4 degrader-1

Cat. No.: HY-149236

CAS No.: 2916433-81-1

Purity: 99.35%

Target:

PROTACs Glutathione Peroxidase Ferroptosis Reactive Oxygen Species (ROS)

Research Areas:

Cancer

PROTAC GPX4 degrader-1 is a glutathione peroxidase 4 (GPX4) PROTAC degrader with a DC₅₀ of 30 nM. PROTAC GPX4 degrader-1 induces ROS accumulation and ferroptosis in cancer cells. PROTAC GPX4 degrader-1 inhibits cell growth and reduces GPX4 levels in tumor tissues. PROTAC GPX4 degrader-1 can be used in research related to various cancers including fibrosarcoma, non-small cell lung cancer, and melanoma .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Ordastobart

Cat. No.: HY-P991336

CAS No.: 2708115-83-5

Synonyms: INBRX-106; ES-102

Ordastobart (INBRX-106; ES-102) is a hexavalent OX40 agonist antibody. Ordastobart enhances OX40 receptor clustering, signaling, and downstream activation, thereby increasing the proliferation and activation of CD4 ⁺ and CD8 ⁺ T cells in vitro and in vivo. Ordastobart exhibits anti-tumor effects and improves survival in mouse models of cancer. Ordastobart is indicated for research in cancers such as fibrosarcoma and colorectal cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

Viridicatol

Cat. No.: HY-116474

CAS No.: 14484-44-7

Purity: 99.93%

Category:

Infection Alkaloids Microorganisms Monophenols Phenols Quinoline Alkaloids Disease Research Fields

Target:

ERK JNK MMP p38 MAPK STAT Fungal Bacterial NO Synthase PGE synthase NF-κB Wnt β-catenin

Viridicatol is a quinolone alkaloid with anti-inflammatory, antibacterial, antifungal, osteogenic and chondrogenic activities. Viridicatol reduces the phosphorylation levels of ERK, JNK, p38 and STAT6; inhibits MMP-2, MMP-9, NF-κB signaling pathway and PTP1B; downregulates genes related to mast cell activation; and binds to SHN3 to activate the Wnt/SHN3 signaling pathway. Viridicatol inhibits the expression of pro-inflammatory mediators and cytokines, and promotes osteogenic/chondrogenic differentiation. Viridicatol can be used in studies related to fibrosarcoma, allergy, bacterial infection, fungal infection and osteoporosis .

Compare

loading...